Related Experiment Video
Updated: Jan 21, 2026
Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
Published on: October 20, 2023
The Challenges of Pediatric Drug Development
1klausrose Consulting, Riehen, Switzerland.
Insights
Regulatory demands for pediatric drug studies often lack medical rationale, potentially harming children by restricting access to superior treatments. Such studies should prioritize genuine medical needs and avoid conflicts of interest.
Area of Science:
- Pharmacology and Therapeutics
- Regulatory Science
- Pediatric Medicine
Background:
- Current "pediatric drug development" focuses on regulatory requirements for pediatric labels, not solely on children's specific needs.
- Regulatory definitions of "children" (<17/18 years) for drug studies are age-based, often disregarding physiological maturity.
- Historical context reveals these requirements emerged partly for legal protection, influencing medical interpretations.
Purpose of the Study:
- To examine the medical rationale behind separate pediatric efficacy and safety (E&S) studies mandated by regulatory authorities (FDA/EMA).
- To analyze the impact of these studies on pediatric patient care and access to therapies.
- To identify potential conflicts of interest associated with increased pediatric clinical trial activity.
Main Methods:
- Analysis of industry-sponsored pediatric E&S studies registered on ClinicalTrials.gov.
- Review of historical US/EU legislation and regulatory documents concerning pediatric drug approval.
- Examination of published literature and justifications from regulatory bodies and the American Academy of Pediatrics (AAP).
Main Results:
- Regulatory age definitions for childhood in drug studies are non-physiological, blurring medical and legal boundaries.
- Warnings about drug dangers in children, including adolescents, are often exaggerated, driven by liability concerns and parental fears.
- This has led to increased pediatric clinical trial activity, creating potential conflicts of interest related to funding and commercial profits.
Conclusions:
- Many FDA/EMA-mandated "pediatric" studies lack medical justification and can impede access to more effective treatments for young patients.
- Separate drug labels for different indications are medically sensible, but separate approvals based solely on age (17/18 years) are not.
- Pediatric research should focus on genuine medical needs, avoid limiting access to superior therapies, and rigorously address conflicts of interest.
Introduction And Background:
"Pediatric Drug Development" is being used to describe not the development of drugs for children, but rather the planning & conducting separate efficacy and safety (E&S) studies requested/demanded by regulatory authorities designed to produce pediatric labels. Pediatric studies required for drug approval enroll "children"; defined as <17 years of age (US Food and Drug Administration [FDA])/ <18 years (European Union [EU]). The medical rationale for study designs was examined.
Material & Methods:
International industry-sponsored pediatric E&S studies registered in www.clinicaltrials.gov were analysed along with the history of US/EU laws, published literature, internet-retrieved regulatory documents, and regulatory/ American Academy of Pediatrics (AAP) justifications for doing separate pediatric E&S studies.
Results:
US/EU regulators utilize an official, but non-physiological definition of childhood based on an age limit of 17/18 years. This definition, which blurs the interface between medicine and law, emerged after clinical studies became required for drug approval in 1962 prompting drug manufacturers to insert pediatric warnings into product information. Intended largely as legal protection against liability, they were interpreted medically. Absorption, distribution, metabolism, excretion mature rapidly. Drug toxicities seen in newborns during the first months of life were cited by AAP/FDA in warnings of dangers of drugs in all "children" including in adolescents who are physiologically no longer children. Warnings were/are exaggerated, exploit/ed parents' protective instincts and fears, and increase/d pediatric clinical trial activity. Conflicts of interest created by this increased activity involve research funding, career status & advancement, commercial profits.
Discussion:
FDA/EMA-requested/demanded "pediatric" studies were identified which lack medical sense at best, others actually harm young patients by impeding use of superior, effective treatments. Separate labels for different indications make medical sense; separate approval in persons above/below 17/18 years of age does not.
Conclusions:
Pediatric medical research should be restricted to studies which meet important medical needs of all recruited young patients, which generate information that cannot be obtained by other study designs, and do not limit access to superior alternative therapies. Clinical centers, investigators, and IRBs/ECs should more carefully examine studies for unjustified regulatory demands, prevention of subjects' access to superior treatments, and undeclared COI's. Questionable studies should not be approved and ongoing ones should be suspended.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:10In Vitro Drug Release Testing: Overview, Development and Validation
01:43Sustainable Development